Cisplatin-induced ototoxicity in patients receiving concurrent chemoradiation in carcinoma cervix

Hanan M, Kutty CKK, Sameer P, Jayaraman MB

Pdf Page Numbers :- 141-146

Hanan M¹, Kunhalan Kutty CK¹, Sameer P² and Jayaraman MB^3,*

¹Department of Radiotherapy, Government Medical College, Kozhikode, Kerala-673008, India

²Department of ENT, Government Medical College, Kozhikode, Kerala-673008, India

³Department of Radiation Oncology, Government Medical College, Thrissur, M. G. Kavu, Kerala-680596, India

*Corresponding author: Dr. Jayaraman MB, Associate professor, Department of Radiation Oncology, Government Medical College, Thrissur, M. G. Kavu, Kerala-680596, India. Email: drjayaramanmb@gmail.com

Received 21 March 2022; Revised 17 May 2022; Accepted 25 May 2022; Published 6 June 2022

Citation: Hanan M, Kutty CKK, Sameer P, Jayaraman MB. Cisplatin-induced ototoxicity in patients receiving concurrent chemoradiation in carcinoma cervix. J Med Sci Res. 2022; 10(3):141-146. DOI: http://dx.doi.org/10.17727/JMSR.2022/10-26

Copyright: © 2022 Hanan M et al. Published by KIMS Foundation and Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PDF

Abstract

Background: Weekly cisplatin at 40mg/m2 is the most common regimen followed in our institution. However, patients receiving cisplatin can experience high-frequency hearing loss due to its expansive toxicity profile, a side effect known as ototoxicity. The dearth of information on the extent and severity of cisplatin-associated ototoxicity prevents implementing a context-specific audiological monitoring program. The study aimed to determine the extent and severity of cisplatin ototoxicity in patients receiving concurrent chemoradiation in carcinoma cervix.

Methods: Otoscopic examinations and audiological investigations were undertaken at regular intervals in patients undergoing concurrent chemoradiation for carcinoma cervix with single-agent cisplatin in the Department of Radiation Oncology, with the aid of the Department of ENT. All the audiological investigations were provided free of cost. Sixty-six patients who met the inclusion criteria were sent for audiological evaluation before the start of chemotherapy, immediately after chemotherapy completion and after one month following chemotherapy.

Results: The study found that cisplatin was associated with high frequency, predominantly bilateral sensorineural hearing loss. Among 66 patients, seven patients (11%) developed cisplatin-induced hearing loss. However, most of the patients developed mild and minimal hearing loss.

Conclusion: The study concluded that patients receiving concurrent chemoradiation for carcinoma cervix with cisplatin developed predominantly bilateral, high-frequency sensorineural hearing loss. However, most patients developed minimal or mild hearing loss.

Keywords: carcinoma cervix; cisplatin; ototoxicity; hearing loss